-
-
-
-
-
-
-
Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy
-
-
-
-
-
-
-
Theravance Biopharma (TBPH) Misses Q4 EPS by 11c ; Provides Outlook
-
-
-
-
-
-
-
Theravance Biopharma (TBPH) Misses Q2 EPS by 13c, provides guidance
-
-
-
-
-
-
-
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
-
-
-
-
-
-
-
Theravance Biopharma to Report Second Quarter 2023 Financial Results on August 7, 2023
-
-
-
-
-
-
-
Irenic Sends Letter to Theravance Biopharma Regarding the Urgent Need for a Governance Overhaul, Capital Return and Strategic Review
-
-
-
-
-
-
-
Theravance Biopharma (TBPH) to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma (RPRX) for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

